Long-Term miR-669a Therapy Alleviates Chronic Dilated Cardiomyopathy in Dystrophic Mice

Mattia Quattrocelli, PhD; Stefania Crippa, PhD; Celeste Montecchiani, MBiolSc; Jordi Camps, MBiolSc; Antonia Icaro Cornaglia, PhD; Luisa Boldrin, PhD; Jennifer Morgan, PhD; Alberto Calligaro, PhD; Andrea Casasco, MD; Aldo Orlacchio, PhD; Rik Gijsbers, PhD; Jan D’Hooge, PhD; Jaan Toelen, MD, PhD; Stefan Janssens, MD, PhD; Maurilio Sampaolesi, PhD

Background—Dilated cardiomyopathy (DCM) is a leading cause of chronic morbidity and mortality in muscular dystrophy (MD) patients. Current pharmacological treatments are not yet able to counteract chronic myocardial wastage, thus novel therapies are being intensely explored. MicroRNAs have been implicated as fine regulators of cardiomyopathic progression. Previously, miR-669a downregulation has been linked to the severe DCM progression displayed by Sgcb-null dystrophic mice. However, the impact of long-term overexpression of miR-669a on muscle structure and functionality of the dystrophic heart is yet unknown.

Methods and Results—Here, we demonstrate that intraventricular delivery of adeno-associated viral (AAV) vectors induces long-term (18 months) miR-669a overexpression and improves survival of Sgcb-null mice. Treated hearts display significant decrease in hypertrophic remodeling, fibrosis, and cardiomyocyte apoptosis. Moreover, miR-669a treatment increases sarcomere organization, reduces ventricular atrial natriuretic peptide (ANP) levels, and ameliorates gene/miRNA profile of DCM markers. Furthermore, long-term miR-669a overexpression significantly reduces adverse remodeling and enhances systolic fractional shortening of the left ventricle in treated dystrophic mice, without significant detrimental consequences on skeletal muscle wastage.

Conclusions—Our findings provide the first evidence of long-term beneficial impact of AAV-mediated miRNA therapy in a transgenic model of severe, chronic MD-associated DCM. (J Am Heart Assoc. 2013;2:e000284 doi: 10.1161/JAHA.113.000284)

Key Words: cardiomyopathy • microRNAs • miRNA therapy • muscular dystrophy

Muscular dystrophies (MDs) constitute a heterogeneous group of hereditary disorders, mainly characterized by chronic muscle degeneration. MDs encompass, among others, dystrophinopathies (eg, Duchenne MD [DMD]) and sarcoglycanopathies (eg, recessive limb girdle MD [LGMD2]) forms. Dystrophin and sarcoglycans are components of the dystrophin-associated glycoprotein complex (DGC). Genetic disruption of DGC components leads to pathological calcium leakage and chronic muscle fiber wastage. Beside skeletal muscle impairment, chronic cardiomyopathy occurs in almost all DMD patients who survive beyond their third decade, and in 30% of LGMD2 patients. MD-associated cardiomyopathy is characterized by arrhythmias, myocardial ischemia, cardiomyocyte necrosis, and fibrotic infiltrations. Affected myocardium undergoes hypertrophic remodeling and ventricular dilation, resulting in progressive functional deterioration (dilated cardiomyopathy [DCM]).

Currently, gene therapy is regarded as a promising tool for reducing or countering cardiomyopathy progression in MDs. However, gene therapy approaches must carefully address the choice of animal models, vector types, and expressed genes.
Animal models of MD-associated cardiomyopathy should confront its complex and chronic manifestations. *mdx* mice genetically mimic DMD, but exhibit cardiomyopathic features prevalent after 20 months of age. Conversely, *Sgcb*-null mice, which genetically model LGMD2E sarcoglycanopathy, already show necrotic foci in 9-week-old hearts and prominent signs of ischemic-like lesions, arrhythmia, and DCM from 20 weeks of age. Notably, cardiomyopathy in *Sgcb*-null mice features severe, chronic progression, and variable worsening with age.

Because of its internal structure and well-protected position, cardiac muscle therapy still poses challenges to vector delivery and fiber transduction. Adeno-associated viral (AAV) vectors appear to be a promising tool for efficient gene delivery in dystrophic hearts. Direct delivery of AAV-micro-dystrophin into the cardiac cavity of newborn *mdx* mice resulted in micro-dystrophin expression and DGC restoration in extensive myocardial areas. AAV-mediated micro-dystrophin delivery has been recently tested in the myocardium of 21-month-old *mdx* mice, partially mitigating electrocardiogram (ECG) abnormalities, but not fibrosis and most hemodynamic parameters. Albeit promising in short term studies, the potential of AAV-based therapies in chronic cardiac dysfunctions remains largely unexplored in the long term.

Suitable candidates for heart gene therapy can be identified in missing genes or cardiomyogenic factors, but also noncoding RNAs, such as microRNAs (miRNAs). MicroRNAs are small, untranslated RNAs able to finely tune expression or translational levels of downstream genes in a wide range of processes, including cardiomyopathy and dysfunctional heart remodeling. Cardiac-specific deletion of *Dicer*, an essential endoribonuclease for miRNA processing, led to DCM and heart failure. Altered levels of *miR*-1 and *miR*-133a were implicated in cardiomyopathic and arrhythmogenic processes, whereas *miR*-208a upregulation was associated with adverse clinical outcome in DCM patients. Moreover, *miR*-669a downregulation has been recently shown to couple calcium leakage and abnormal *MyoD* expression in chronic DCM of *Sgcb*-null mice. However, assessment of long-term effects of microRNA therapies in in vivo models of chronic cardiomyopathy is still lacking.

In the present study, we investigated the long-term (18 months) effects of AAV-mediated intraventricular *miR*-669a delivery in *Sgcb*-null mice. Therapeutic relevance of this approach was assessed by measuring histologic, molecular, and functional properties of MD-associated end-stage chronic cardiomyopathy. We show that *miR669a* expression is maintained up to 18 months postinjection and results in increased mice viability and marked reduction of adverse hypertrophic remodeling and myocardial fibrosis. Furthermore, such miRNA therapy consistently alleviates cardiomyopathic progression and increases left ventricular performance, as evidenced by protein, gene and microRNA markers, and by functional parameters. In addition, *miR*-669a delivery fails in triggering off-target effects in the skeletal muscle of treated mice. In summary, our study provides the first evidence of long-term, beneficial effects of AAV-mediated in vivo miRNA therapy of MD-associated advanced chronic cardiomyopathy.

**Materials and Methods**

**Animal Procedures**

All animal protocols were conducted in compliance with Ethical Committee Guidelines of KU Leuven (project 095/2012) and Belgian legislation. *Sgcb*-null mice were generated by the group of K.P. Campbell (University of Iowa). Recombinant AAV vectors were produced as previously described.19 10⁸ AAV2/9 particles in 10 μL PBS (sham, 10 μL PBS only) were delivered into pups (sham, n=15; miR-dsRed, n=15; *miR*-669a, n=15; randomized groups) through intraventricular puncture through the chest wall within 24 hours after birth. Survival was monitored during 18 months. At 18 months postinjection, all surviving mice (sham, n=3; miR-dsRed, n=3; *miR*-669a, n=7) were analyzed using echocardiography and subsequently euthanized for histologic and molecular analyses.

**Histologic Analyses**

Cardiac and skeletal muscle OCT-embedded transversal cryosections were stained via Artisan Staining kit (Dako) for Masson's trichromic staining after fixation in paraformaldehyde (4% paraformaldehyde [PFA] in PBS, 30 minutes at room temperature) and Bouin's solution (8 hours at room temperature), according to manufacturer's protocol. Sirius Red staining was performed on formalin-embedded transverse, 5-μm-thick sections using Direct Red 80 reagent (Sigma) as previously described, and pictures were taken with polarized light and appropriate filter at Leica DM5500B microscope. X-Gal staining was performed by overnight incubation at 37°C of gluteraldehyde-fixed cryosections with ready-to-use X-Gal staining solution (Fermentas), followed by subsequent eosisin (Sigma) counterstaining. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed on cryosections, after fixation first in PFA, then in ethanol/acetic acid, by Apoptag kit (Millipore), according to manufacturer's instructions. Bright field and fluorescence images were acquired at 10× magnification via Eclipse Ti inverted microscope (Nikon) and quantifications were conducted on >10 sections per mouse via ImageJ software. As regards transmission electron microscopy, immersion fixation was performed by incubating the ventricle biopsies in PBS supplemented with 4% PFA and 0.5% gluteraldehyde at 4°C.
for 4 hours. The samples were washed with PBS, carefully minced, postfixed in 1% osmium tetroxide in colloidine buffer for 1 hour at 4°C, then dehydrated through ice-cold gradient EtOH series (25%, 50%, 75%, 80%, 90% and 100%) for 15 minutes each. Tissue samples were then routinely embedded in Epon, ultrathin-sectioned (75 to 90 nm) and placed on nickel grids. Grids were stained with a saturated solution of uranyl acetate followed by Reynold’s lead citrate, then examined by EM10 Zeiss Electron Microscope.

Immunostaining and Western Blot Analysis

Immunostaining reactions were performed on PFA-fixed, TritonX100-permeabilized (Sigma) transverse, 10-μm-thick cryosections by overnight incubation at 4°C with primary antibody in PBS supplemented with 5% w/v BSA (Sigma). Primary antibodies and dilutions were as follows: chicken antilaminin (Abcam), 1:300; mouse antisarcomeric α-actinin (Abcam), 1:300; rabbit anti-Cx43 (SantaCruz), 1:300. All secondary Alexa Fluor donkey antibodies (Life Technologies) were diluted 1:500 in PBS supplemented with 5% w/v BSA. Fluorescence images were acquired at 20× magnification via Eclipse Ti inverted microscope (Nikon). Western blot (WB) analysis was performed on 10 μg protein extracts on parallel gels and primary antibody was incubated with nitrocellulose blots overnight at 4°C in Tris-buffered saline (TBS) supplemented with 5% w/v skim milk powder (Sigma). Primary antibodies and dilutions were as follows: rabbit anti-Cx43 (SantaCruz), 1:500; rabbit antiatrial natriuretic peptide (ANP) (Millipore), 1:500. All secondary horseradish peroxidase (HRP)-conjugated goat antibodies (SantaCruz) were diluted 1:5000 in TBS supplemented with 5% w/v skim milk powder. WB imaging was performed on GelDoc chemiluminescence detection system (BioRad) and protein levels were quantified by relative densitometry, normalizing versus background and Gapdh, through QuantityOne software (BioRad).

Gene/miRNA Expression Analyses

RNA was extracted from ≈10 mg cardiac tissue of all surviving mice through miRNA isolation kit (Life Technologies). Reverse transcription and Taqman-based qPCR were conducted using miRNA-specific probes (Life Technologies). Expression quantification was normalized versus miR-16 levels.

Functional Assessment

Mice were anesthetized using Isoflurane (1.5% to 2%, Ecuphar). Subsequently, the animal was positioned in a supine position on a heating pad and chest hair was removed using a hair removing cream (Veet). Body temperature was kept constant by feeding the signal of a rectal probe back to the heating pad while heart and respiratory rates were continuously monitored. Transthoracic echocardiography was performed using a high frequency ultrasound system dedicated to small animal imaging (VisualSonics Vevo 2100, VisualSonics Inc) using a MS 400 linear array transducer (18 to 38 MHz). Parasternal short axis images at the level of the papillary muscles were recorded as well as a parasternal long axis image. All images were analyzed offline using dedicated software (Vevo 2100 version 1.3, VisualSonics). Left ventricle (LV) diameter at end-diastole (LVDD) and end-systole (LVDS), and posterior wall thickness (PWT) were measured on the short axis images as well as apex-to-base dimension of the LV on the long axis image. From these measurements, fractional shortening (FS) was calculated.

Skeletal Muscle Analyses

Transverse 7-μm-thick cryosections of soleus, tibialis anterior, and diaphragm muscles, embedded in Tragacanth Gum, were rehydrated with PBS and analysed for the presence of satellite cells as previously described.23 Briefly, after blocking, muscle sections were stained with primary Pax7 (Hybridoma Bank, Iowa University) and laminin (Sigma) antibodies and appropriate secondary antibodies (Molecular Probes) to identify satellite cells under the basal lamina of muscle fibers. Sections were mounted on polylysine-coated slides with fluorescent mounting medium (DAKO) containing DAPI (10 μg/mL). Fluorescence images were taken using a Zeiss Axioscope microscope (Carl Zeiss) and Metamorph image capture software (Metamorph Production). Numbers of satellite cells per muscle fiber in representative transverse sections were counted and presented as percentages of satellite cells.

Statistical Analysis

Survival curves were analyzed with Mantel-Cox and Gehan-Breslow-Wilcoxon tests. Variation significance was scored when P<0.05 in both tests (*in figures and text). All
Results

In Vivo miR-669a Therapy Ameliorates Survival and is Maintained Long-Term

To determine long-term efficacy and maintenance of in vivo miR-669a therapy, AAV2/9 vectors bearing nuclear LacZ cDNA (nLacZ) as tracer and, alternatively, two copies of anti-dsRed miRNA (miR-dsRed) or miR-669a, as control scramble and therapeutic miRNAs respectively, were generated and concentrated as reported (Figure S1,21). Newborn Sgcb-null dystrophic mice were randomized into three groups and injected with PBS (sham, n=15), AAV2/9-miR-dsRed (miR-dsRed, n=15), or AAV2/9-miR-669a (miR-669a, n=15) intraventricularly, and survival was monitored for 18 months. Analysis of fatalities over time indicated that only miR-669a treatment, but not miR-dsRed, did significantly improve mice survival, as compared to sham (Figure 1A).

In order to check for long-term maintenance of injected vectors and expression of target miRNAs and tracers, the myocardium of all mice surviving at 18 months postinjection was analyzed for miR-669a and nLacZ expression. Quantitative PCR (qPCR) data showed a significant increase in miR-669a levels only in miR-669a mice, as compared to sham and miR-dsRed (Figure 1B). X-Gal histological staining revealed virtually ubiquitous nLacZ expression throughout the myocardium both in miR-dsRed and in miR-669a mice (Figure S2).

Thus, AAV-mediated miR669a therapy is maintained for at least 18 months and miR-669a-treated, Sgcb-null mice show significant amelioration of survival rate over time, as compared to controls.

miR-669a Expression Ameliorates Myocardial Hypertrophy and Fibrosis

Hypertrophic remodeling and myocardial fibrosis are hallmark signs of MD-associated DCM. In order to assess miRNA therapy effects on ventricular hypertrophy, we analyzed morphological pattern and cross-sectional area (CSA) values of cardiomyocytes, as previously reported.24 Immunostaining on myocardial sections revealed a heterogeneously unorganized pattern of enlarged cardiomyocytes in sham and miR-dsRed, whereas cardiomyocytes appeared smaller and more compactly organized in miR-669a (Figure 1C). Accordingly, quantitative analyses showed that treatment with miR-669a significantly decreased average cardiomyocyte CSA (Figure S3) and dramatically shifted CSA value distribution toward lower classes (Figure 1D), as compared to sham and miR-dsRed.

We next asked whether treatment with miR-669a induced beneficial effects on myocardial fibrosis and cardiomyocyte apoptosis. Fibrotic areas were revealed by histological staining and quantified as percentage of total section area. Quantitative analysis of intramyocardial fibrotic areas using Masson’s trichromatic staining indicated a significant reduction in miR-669a mice, as compared to sham and miR-dsRed (Figure 1E and Figure S4). Comparable results were quantifiable after Sirius Red staining of collagen deposits (Figure S5). Pyknotic nuclei quantification by TUNEL assay, moreover, revealed a significant reduction in apoptotic nuclei in miR-669a mice, as compared to sham and miR-dsRed (Figure S6).

Ventricular myocardium under chronic DCM conditions is also characterized by impairment of sarcomeric structures,25 and gap junctions,26 and by increased local release of ANP.27 Because of the beneficial effects of miR-669a therapy on hypertrophy, fibrosis, and apoptosis, we sought to determine whether miR-669a treatment triggered long-term effects also on sarcomere organization, connexin-43 (Cx43) pattern, and ANP levels. Transmission electron microscopy imaging revealed disrupted and variably orientated myofibrils in sham and miR-dsRed myocardia, whereas sarcomere organization was partially restored and de novo-forming myofibrils were visible after miR-669a treatment (Figure 1F). Immunostaining revealed ameliorated Cx43 pattern at intercalated disks in miR-669a mice, as compared to sham and miR-dsRed (Figure 1G). Furthermore, protein analysis revealed that an increase in Cx43 quantity and a decrease in ANP levels were also significantly quantifiable in the ventricular myocardium of miR-669a mice, as compared to sham and miR-dsRed (Figure 1H and Figure S7).

Hence, miR-669a therapy ameliorated hypertrophic remodeling, fibrosis, and structural organization of end-stage Sgcb-null myocardium.

miR-669a Expression Alters Cardiomyopathic Gene/miRNA Signature

Given the long-term effects on survival and histological properties, we then asked whether AAV-mediated miR-669a therapy was also sufficient to perturb transcription levels of gene and miRNA markers of cardiomyopathy.

We examined myocardial levels of Myod, abnormally reactivated in Sgcb-null cardiac cells and a direct target of miR-669a,21 and of Agrp1a, Il6 and Il1b, which were previously shown to be upregulated in hypertrophic cardiomyopathy.28–30
Quantitative PCR data indicated significant downregulation of all gene markers in miR-669a mice, as compared to sham and miR-dsRed (Figure 2A).

Furthermore, we investigated potential alterations in expression levels of miRNAs implicated in hypertrophy, cardiac degeneration, and DCM. Beside miR-1, miR-133a, and miR-208a, we quantified expression levels of miR-21, miR-378, and miR-499, previously reported to be upregulated during cardiomyopathy or cardiomyocyte stress.\(^{31-33}\) Quantitative PCR data showed significant downregulation of miR-1 and miR-208a and upregulation of miR-133a in the myocardium of miR-669a mice, as compared to sham and miR-dsRed (Figure 2B). In addition, miR-21, miR-378, and miR-499 were also significantly downregulated (Figure 2B).
Thus, miR-669a sustained expression was sufficient to trigger long-term perturbation of many gene/miRNA markers of cardiomyopathy.

**Long-Term miR-669a Expression Alleviates Cardiac Functional Impairment**

DCM progression affects not only histologic and contractile, but also functional properties of the myocardium, resulting in dilation of ventricular chambers, augmentation of posterior wall thickness, and reduction of systolic fractional shortening. We therefore investigated whether miR-669a treatment affected functional cardiac properties in all surviving mice at 18 months postinjection, using transthoracic echocardiography. Possible effects on DCM-related cardiac dysfunction were measured by quantifying long axis of LV, posterior wall thickness, ventricle diameter, and fractional shortening.

Treatment with miR669a, but not with miR-dsRed, significantly reduced the end-diastolic long axis dimension of the LV (Lax-endo, Figure 3A). Moreover, posterior wall thickness showed a significant decrease in miR-669a mice, as compared to sham and miR-dsRed (PWT, Figure 3A). Importantly, long-term miR-669a expression significantly decreased LV internal diameter both in diastole and in systole (LVIDd and LVIDs respectively, Figure 3B) and, as a consequence, increased the systolic fractional shortening, as compared to sham and miR-dsRed (Figure 3C).

Hence, echocardiography-based quantifications demonstrated significant alleviation of DCM dysfunctional phenotype in miR-669a-treated mice at 18 months postinjection.

**AAV-Mediated miRNA Therapy Does not Present Off-Target Detrimental Effects in the Skeletal Muscle**

Because of the dramatic negative regulation exerted by miR-669a on MyoD and the tropism of AAV serotype 2/9 also for skeletal muscle, we next sought to assess potential long-term effects of AAV-mediated miRNA therapy on skeletal muscle structure of injected dystrophic mice. In addition, satellite cell (SC) number was also investigated, as an indication of regenerative capability of the skeletal muscle. Hind limb and diaphragm muscles of all surviving mice were therefore analyzed for fibrosis extension, fiber diameter, and SC percentage per fiber.

X-Gal histological staining showed virtually absent nLacZ expression in the skeletal muscles of sham, miR-dsRed, and miR-669a mice (Figure S8A). Masson's trichromic staining revealed deep fibrotic infiltrations in gastrocnemius muscles in all three experimental conditions, without significant differences (Figure S8B). Moreover, no significant differences were quantifiable in average CSA (Figure S9) or CSA value distribution of gastrocnemius fibers among sham, miR-dsRed, and miR-669a conditions (Figure 4A). Similar results were also obtained by analyzing the quadriceps muscles (data not shown). In addition, no significant differences were found when quantifying the SC percentage/fiber in diaphragm, tibialis anterior, and soleus muscles among the three experimental conditions (Figure 4B).

Thus, AAV-mediated intraventricular delivery of both miR-dsRed and miR-669a did not result in significant deleterious effects on morphology and regenerative potential of hind limb and diaphragm muscles of treated mice as compared to sham conditions.

---

**Figure 2.** Effects of long-term miR-669a-based therapy on gene/miRNA profile of Sgcb-null hearts. A, qPCR data indicate significant decrease of MyoD, Agt1a, Il6 and Il1b expression levels in miR-669a-treated myocardium (fold change normalized vs sham). B, Expression levels of mir-1, mir-208a, mir-21, mir-378 and mir-499 significantly decrease, while mir-133a levels increase, in miR-669a–treated myocardium (fold change normalized vs sham). Error bars depict standard deviation; **P<0.05 vs sham and P<0.05 vs miR-dsRed. Sham, n=3; miR-dsRed, n=3; miR-669a, n=7. miRNA indicates MicroRNA; qPCR, quantitative polymerase chain reaction.
Discussion

MD-associated DCM is currently treatable only by symptom alleviation, as effective cardioprotective or reparative intervention is yet lacking. Taken together, our results provide the first evidence of long-term beneficial effects of a miRNA therapy in a murine model of MD-associated DCM. In fact, AAV-mediated miR-669a expression is maintained for at least 18 months in Sgcb-null hearts, significantly improves myocardial structure and function, and reduces adverse left ventricular remodeling, thereby increasing survival rate of dystrophic, severely cardiomyopathic mice.

In our study, Sgcb-null dystrophic mice constituted a suitable model to assess long-term effects and efficacy of AAV-mediated miRNA therapy. In fact, spontaneous, early onset, and severe, chronic progression of DCM constitute a challenging yet clinically relevant model to test novel therapeutic approaches. Interestingly, miR-669a-mediated effects were consistently quantifiable at 18 months postinjection, corresponding to an end-stage point with regards to both life expectancy and severity of cardiomyopathy in these mice.

In our approach, AAV2/9 vectors were tested. AAV vectors are gathering increasing interest in the cardiac gene therapy field, given the susceptibility of cardiomyocytes to AAV transduction.38 In addition, the 2/9 serotype recently showed high tropism for the cardiac muscle also in nonhuman primates.39 A possible drawback of AAV-based therapies resides in variable immune response against viral capsids or occasionally against AAV-transduced host cells.40,41 The main limitation of the present study is that AAV particles were injected before 24 hours after birth, escaping possible immune responses by the developing host immune system. In this regard, detailed studies are yet required to determine immunological sustainability over time of such an AAV therapy in juvenile or adult dystrophic mice.

Given the small size of miRNA molecules, many alternatives to viral vectors are currently tested for cardiac miRNA delivery or blockade, including injection of chemically modified oligonucleotides.42 Oligonucleotide-based approaches could bypass the obstacles posed by immune response and viral genome integration, although durability and need of repeated injections might still hamper applications on MD-associated DCM cases.43 Our results indicate that a single AAV injection is able to partially counteract cardiomyopathic progression for up to 18 months in a small animal model of MD-associated DCM.

In our experimental conditions, histological, protein, and molecular assays showed significant miR-669a-dependent reduction of myocardial hypertrophy, apoptosis, and fibrosis. In accordance with previously reported data,21 miR-669a overexpression was able to diminish aberrant MyoD levels in the dystrophic myocardium also in the long term. MyoD downregulation is likely linked to a decrease in aberrant myogenic fate and in related apoptotic events during

Figure 3. Long-term miR-669a-based therapy alleviates MD-associated dilated cardiomyopathy. Echocardiography-based measurements show a significant improvement in distance between mitral valve and endocardial apex border (Lax-endo) and posterior wall thickness (PWT) (A) decrease in left ventricle internal diameter both in diastole and in systole (LVIdd and LVIds respectively, (B) and increase in the fractional shortening of the left ventricle in miR-669a group, as compared to sham and miR-dsRed (C). Bars, average value; each data point refers to one mouse surviving at 18 months post-injection. **P<0.05 vs sham and P<0.05 vs miR-dsRed; sham, n=3; miR-dsRed, n=3; miR-669a, n=7. MD indicates muscular dystrophy.
remodeling of dystrophic myocardium, thus partially explaining the beneficial effects on treated hearts. Furthermore, we observed potentially beneficial variations also in transcriptional levels of cardiac miRNAs that are involved in cardiomyopathy and cardiac dysfunction. Notably, miR-669-a-injected hearts displayed decreased miR-1 and miR-208a, and increased miR-133a levels. Interestingly, miR-1 was recently reported to suppress Cx43 in a model of myocarditis.44 This could additionally explain Cx43 upregulation in miR-669a-treated hearts. Furthermore, miR-208a downregulation correlates with decreased remodeling, as miR-208a-null mice fail to undergo hypertrophy and fibrosis in response to several forms of cardiac stress.45 Conversely, miR-133a upregulation can counteract Caspase9-mediated apoptosis upon myocardial injury.46 Moreover, miR-133a downregulation has been recently shown to further worsen prohypertrophic calcium signaling and pathological remodeling in the heart.47 However, changes in global miRNA levels could theoretically lead to adverse side events (eg, high miR-133a levels have been associated with retinal degeneration).48 Although far from the scope of this work, a systemic investigation in off-target organs is in fact required to address possible detrimental effects of such miRNA therapies.

Importantly, intraventricular miR-669a delivery ameliorated structure and function of DCM hearts, apparently without inducing off-target detrimental effects in the skeletal muscle. Moreover, after miR-669a treatment, neither the dystrophic muscle wasting, nor the SC percentage was different from control groups. Interestingly, nuclei positive to nlacZ staining were virtually absent in skeletal muscles of AAV-injected mice. Given Mjod-dependent effects on the delicate balance between quiescence and apoptosis in SCs,49 it might be possible that rare miR669a-transduced SCs were eventually withdrawn from the muscles after repeated cycles of de/regeneration, typical of MD progression.

In summary, this study provides the first evidence of long-term (18 months) beneficial effects of AAV-mediated miR-669a therapy in a murine model of MD-associated chronic DCM. Further refinement of administration routes and combination with cell therapy will potentially increase therapeutic effectiveness of miRNA-based strategies for MD cardiomyopathy.

Acknowledgments
AAV-based viral vectors were produced by the Leuven Viral Vector Core. We appreciated Danny Huybrecheek, Karin Sipido, and Catherine Verfaillie for critical discussion. The authors would like to thank Christina Vochten and Vicky Raets for professional secretarial service.

Sources of Funding
The Translational Cardiomyology laboratory is supported by CARE-MI FP7, AFM, CARIPLO, FWO, GOA, IUAP and OT grants. Dr Quattrocelli is supported by a FWO PostDoctoral Fellowship. Dr Morgan is funded by a Wellcome Trust University Award. Dr Boldrin is funded by the BBSRC. Dr Toelen is funded by the KOOR Fonds of the University Hospitals Leuven. The authors would like to thank also Paolo Luban and Rondouf-ons voor Duchenne Onderzoek for kind donations.

Disclosures
None.

References
1. Emery AE. The muscular dystrophies. Lancet. 2002;359:687–695.
2. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res. 2004;94:1023–1031.
3. Gissel H. The role of Ca2+ in muscle cell damage. *Ann N Y Acad Sci*. 2005;1065:161–180.

4. Melo EM. New approaches in the therapy of cardiomyopathy in muscular dystrophy. *Annu Rev Med*. 2007;58:75–88.

5. Malacini P, Fanin M, Duggan DJ, Freda MP, Berardinelli A, Danieli GA, Barchitta A, Hoffman EP, Dalla Volta S, Angelini C. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. *Muscle Nerve*. 1999;22:473–479.

6. Verhaert D, Richards K, Rafael-Fortney JA, Raman SV. Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations. *Circ Cardiovasc Imaging*. 2011;4:67–76.

7. Lai Y, Duan D. Progress in gene therapy of dystrophic heart disease. *Gene Ther*. 2019;12:473–685.

8. Duan D. Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. *Hum Mol Genet* 2006;15 Spec No 2:R253-261.

9. Lefaucheur JP, Pastoret C, Sebille A. Phenotype of dystrophinopathy in old mdx mice. *Anat Rec*. 1995;242:70–76.

10. Durbej M, Cohn RD, Hraska RF, Moore SA, Allamand V, Davidson BL, Hedman M, Hartikainen J, Yla-Herttuala S. Progress and prospects: hurdles to gene therapy: current controversies and translational perspectives. *Hum Gene Ther*. 2012;53:1–27.

11. Orenes-Pinero E, Montoro-Garcia S, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, Nagalingam RS, Gupta M. A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. *J Biol Chem*. 2012;287:12913–12926.

12. Mattikovskij S, Yu Y, Eschenbacher WH, Dorn LE, Dorn GW 2nd. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. *Circ Res*. 2012;111:521–531.

13. Politano L, Negro G. Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. *Acta Myol*. 2012;31:24–30.

14. Carvalho JS, Silva CM, Shibeunaie EA, Redingston AN. Prognostic value of posterior wall thickness in childhood dystrophic cardiomyopathy and myocarditis. *Eur Heart J*. 1996;17:1233–1238.

15. Chun JL, O’Brien R, Berry SE. Cardiac dysfunction and pathology in the dystrophic and utrophin-deficient mouse during development of dilated cardiomyopathy. *Neuromuscul Disord*. 2012;22:368–379.

16. Knezevic I, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, Nagalingam RS, Gupta M. A novel cardiomyocyte-enriched microRNA, miR-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. *J Biol Chem*. 2012;287:12913–12926.

17. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Bagnall RD, Tsoutsman T, Shephard RE, Ritchie W, Semsarian C. Global expression of miRNA pro-cardiomyocytes. *Proc Natl Acad Sci USA*. 2011;108:1626–1632.

18. Bostick B, Shin JH, Yue Y, Wasala NB, Lai Y, Duan D. AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial remodeling and cell survival. *J Mol Cell Cardiol*. 2012;50:129–138.

19. Lai Y, Duan D. Progress in gene therapy of dystrophic heart disease. *Gene Ther*. 2009;16:105–114.

20. Masuda T, Muto S, Fujisawa G, Iwazu Y, Kimura M, Kobayashi T, Nonaka-Sarukawa M, Sasaki N, Watanabe Y, Shinohara M, Murakami T, Shimada K, Kobayashi E, Kusano E. Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy. *Am J Physiol Heart Circ Physiol*. 2012;302:H1871–H1883.

21. Bobbert P, Janke A, Bobbert T, Kuhl U, Rauch U, Lassner D, Scheibenbogen C, Poller W, Schulteis HF, Skurk C. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. *Eur J Heart Fail*. 2012;14:1265–1275.

22. Ock S, Ahn J, Lee SH, Park H, Son JW, Oh JG, Yang DK, Lee WS, Kim HS, Rho J, Oh GT, Abel PD, Park WJ, Min JK, Kim J. Receptor activator of nuclear factor-kappab ligand is a novel inducer of myocardial inflammation. *Cardiaco* 2012;5:1–5.

23. Chun JL, O’Brien R, Berry SE. Cardiac dysfunction and pathology in the dystrophic and utrophin-deficient mouse during development of dilated cardiomyopathy. *Neuromuscul Disord*. 2012;22:368–379.

24. Tackett D, Ritzel R. The role of microRNAs in heart function. *Annu Rev Physiol*. 2012;74:109–129.

25. Lefta M, Campbell KS, Feng HZ, Jin JP, Esser KA. Development of dilated cardiomyopathy in Bmi1-deficient mice. *Am J Physiol Heart Circ Physiol*. 2012;303:H475–H485.

26. Li J, Goossens S, van Hengel J, Gao E, Cheng L, Tyberghein K, Shang X, De Rycke R, van Roy F, Radice GL. Loss of alpha-catatin alters the hybrid adhering junctions in the heart and leads to dilated cardiomyopathy and ventricular arrhythmia following acute ischemia. *J Cell Sci*. 2012;125:1056–1067.

27. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. *Eur Heart J*. 2008;29:1485–1494.

28. Masuda T, Muto S, Fujisawa G, Iwazu Y, Kimura M, Kobayashi T, Nonaka-Sarukawa M, Sasaki N, Watanabe Y, Shinohara M, Murakami T, Shimada K, Kobayashi E, Kusano E. Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy. *Am J Physiol Heart Circ Physiol*. 2012;302:H1871–H1883.

29. Bobbert P, Janke A, Bobbert T, Kuhl U, Rauch U, Lassner D, Scheibenbogen C, Poller W, Schulteis HF, Skurk C. High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. *Eur J Heart Fail*. 2012;14:1265–1275.

30. Ock S, Ahn J, Lee SH, Park H, Son JW, Oh JG, Yang DK, Lee WS, Kim HS, Rho J, Oh GT, Abel PD, Park WJ, Min JK, Kim J. Receptor activator of nuclear factor-kappab ligand is a novel inducer of myocardial inflammation. *Cardiaco* 2012;5:1–5.
45. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. *Science*. 2007;316:575–579.

46. He B, Xiao J, Ren AJ, Zhang YF, Zhang H, Chen M, Xie B, Gao XG, Wang YW. Role of miR-1 and miR-133a in myocardial ischemic postconditioning. *J Biomed Sci*. 2011;18:22.

47. Drawnel FM, Wachten D, Molkentin JD, Maillet M, Aronsen JM, Swift F, Sjaastad I, Liu N, Catalucci D, Mikoshiba K, Hisatsune C, Okkenhaug H, Andrews SR, Bootman MD, Roderick HL. Mutual antagonism between IP3RII and miRNA-133a regulates calcium signals and cardiac hypertrophy. *J Cell Biol* 2012;199:783–798.

48. Loscher CJ, Hokamp K, Kenna PF, Ivens AC, Humphries P, Palfi A, Farrar GJ. Altered retinal microRNA expression profile in a mouse model of retinitis pigmentosa. *Genome Biol*. 2007;8:R248.

49. Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A. MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3. *J Cell Biol*. 2010;191:347–363.